CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study

Key Takeaways CORT said the phase III ROSELLA study met its OS endpoint in platinum-resistant ovarian cancer.Data showed relacorilant plus nab-paclitaxel cut death risk 35% and lifted median OS to 16 months.Corcept said both OS and PFS endpoints were met without biomarker selection or added safety burden.Shares of Corcept Therapeutics (CORT) were up 13.7% on Jan. 22, after the company announced that the phase III ROSELLA study, which evaluated its pipeline candidate, relacorilant in combination with nab-pac ...